Antioxidant, Anti-inflammatory, and Genomic Stability Enhancement Effects of Zinc l-carnosine: A Potential Cancer Chemopreventive Agent?

References

• Stewart BW and Wild CP: World Cancer Report 2014. International Agency for Research on Cancer, Lyon, France, 2014.
   Google Scholar
• Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, et al.: Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 100, 1763–1770, 2008.
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, and Feuer EJ: Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 100, 1755–1762, 2008.
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Lund J, Kepka D, and Mariotto A: Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 20, 2006–2014, 2011.
   PubMed Web of Science ®Google Scholar
• Drummond MF and Mason AR: European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 25, 191–195, 2007.
   PubMed Web of Science ®Google Scholar
• Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360, 626–633, 2009.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Palmer JA, Nadler E, Fang C, and Ubel P: Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood) 29, 196–202, 2010.
   PubMed Web of Science ®Google Scholar
• Galmarini D, Galmarini CM, and Galmarini FC: Cancer chemotherapy: a critical analysis of its 60 years of history. Crit Rev Oncol Hematol 84, 181–199, 2012.
   PubMed Web of Science ®Google Scholar
• Morgan G, Ward R, and Barton M: The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol) 16, 549–560, 2004.
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, et al.: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64, 252–271, 2014.
   PubMed Web of Science ®Google Scholar
• Bhosle J and Hall G: Principles of cancer treatment by chemotherapy. Surgery (Oxford) 27, 173–177, 2009.
   Google Scholar
• Fisher R, Pusztai L, and Swanton C: Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108, 479–485, 2013.
   PubMed Web of Science ®Google Scholar
• Rebucci M and Michiels C: Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 85, 1219–1226, 2013.
   PubMed Web of Science ®Google Scholar
• Marusyk A and Polyak K: Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805, 105–117, 2010.
   PubMed Web of Science ®Google Scholar
• Steward WP and Brown K: Cancer chemoprevention: a rapidly evolving field. Br J Cancer 109, 1–7, 2013.
   PubMed Web of Science ®Google Scholar
• Sporn MB and Suh N: Chemoprevention of cancer. Carcinogenesis 21, 525–530, 2000.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, et al.: Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99, 272–282, 2007.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, et al.: Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16, 67–75, 2015.
   PubMed Web of Science ®Google Scholar
• Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, et al.: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60, 293–297, 2000.
   PubMed Web of Science ®Google Scholar
• Reddy BS, Patlolla JM, Simi B, Wang SH, and Rao CV: Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. Cancer Res 65, 8022–8027, 2005.
   PubMed Web of Science ®Google Scholar
• Matsukura T, Takahashi T, Nishimura Y, Ohtani T, Sawada M, et al.: Characterization of crystalline l-carnosine Zn(II) complex (Z-103), a novel anti-gastric ulcer agent: tautomeric change of imidazole moiety upon complexation. Chem Pharm Bull (Tokyo) 38, 3140–3146, 1990.
   PubMed Web of Science ®Google Scholar
• Salgueiro MJ, Zubillaga M, Lysionek A, Sarabia MI, Caro R, et al.: Zinc as an essential micronutrient: a review. Nutr Res 20, 737–755, 2000.
   Web of Science ®Google Scholar
• Boldyrev AA, Aldini G, and Derave W: Physiology and pathophysiology of carnosine. Physiol Rev 93, 1803–1845, 2013.
   PubMed Web of Science ®Google Scholar
• Ueki S, Seiki M, Yoneta T, Omata T, Hori Y, et al.: Effect of Z-103 on compound 48/80-induced gastric lesions in rats. Scand J Gastroenterol Suppl 162, 202–205, 1989.
   PubMedGoogle Scholar
• Yoshikawa T, Naito Y, Tanigawa T, Yoneta T, Yasuda M, et al.: Effect of zinc-carnosine chelate compound (Z-103), a novel antioxidant, on acute gastric mucosal injury induced by ischemia-reperfusion in rats. Free Radic Res Commun 14, 289–296, 1991.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Yamaguchi T, Yoshida N, Yamamoto H, Kitazumi S, et al.: Effect of Z-103 on TNB-induced colitis in rats. Digestion 58, 464–468, 1997.
   PubMed Web of Science ®Google Scholar
• Ohkawara T, Takeda H, Kato K, Miyashita K, Kato M, et al.: Polaprezinc (N-(3-aminopropionyl)-l-histidinato zinc) ameliorates dextran sulfate sodium-induced colitis in mice. Scand J Gastroenterol 40, 1321–1327, 2005.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M and Kishi S: Prolonged administration of beta-alanyl-l-histidinato zinc prevents bone loss in ovariectomized rats. Jpn J Pharmacol 63, 203–207, 1993.
   PubMedGoogle Scholar
• Yamaguchi M: beta-Alanyl-l-histidinato zinc and bone resorption. Gen Pharmacol 26, 1179–1183, 1995.
   PubMedGoogle Scholar
• Kato S, Tanaka A, Ogawa Y, Kanatsu K, Seto K, et al.: Effect of polaprezinc on impaired healing of chronic gastric ulcers in adjuvant-induced arthritic rats—role of insulin-like growth factors (IGF)-1. Med Sci Monit 7, 20–25, 2001.
   PubMedGoogle Scholar
• Seto K, Yoneta T, Suda H, and Tamaki H: Effect of polaprezinc (N-(3-aminopropionyl)-l-histidinato zinc), a novel antiulcer agent containing zinc, on cellular proliferation: role of insulin-like growth factor I. Biochem Pharmacol 58, 245–250, 1999.
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Matsumura H, Nakamura H, Oshiro S, Arakawa Y, et al.: Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. J Clin Biochem Nutr 45, 292–303, 2009.
   PubMed Web of Science ®Google Scholar
• Matsumura H, Nirei K, Nakamura H, Arakawa Y, Higuchi T, et al.: Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C. J Clin Biochem Nutr 51, 178–184, 2012.
   PubMed Web of Science ®Google Scholar
• Sakagami M, Ikeda M, Tomita H, Ikui A, Aiba T, et al.: A zinc-containing compound, polaprezinc, is effective for patients with taste disorders: randomized, double-blind, placebo-controlled, multi-center study. Acta Otolaryngol 129, 1115–1120, 2009.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Kurono Y, Inokuchi A, Takeda N, Aiba T, et al.: The effect of zinc agent in 219 patients with zinc deficiency-inductive/idiopathic taste disorder: a placebo controlled randomized study. Nippon Jibiinkoka Gakkai Kaiho 116, 17–26, 2013.
   PubMedGoogle Scholar
• Yoshikawa T, Naito Y, Tanigawa T, Yoneta T, and Kondo M: The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-l-histidinato zinc. Biochim Biophys Acta 1115, 15–22, 1991.
   PubMed Web of Science ®Google Scholar
• Hiraishi H, Sasai T, Oinuma T, Shimada T, Sugaya H, et al.: Polaprezinc protects gastric mucosal cells from noxious agents through antioxidant properties in vitro. Aliment Pharmacol Ther 13, 261–269, 1999.
   PubMed Web of Science ®Google Scholar
• Shimada T, Watanabe N, Ohtsuka Y, Endoh M, Kojima K, et al.: Polaprezinc down-regulates proinflammatory cytokine-induced nuclear factor-kappaB activiation and interleukin-8 expression in gastric epithelial cells. J Pharmacol Exp Ther 291, 345–352, 1999.
   PubMed Web of Science ®Google Scholar
• Ohata S, Moriyama C, Yamashita A, Nishida T, Kusumoto C, et al.: Polaprezinc protects mice against endotoxin shock. J Clin Biochem Nutr 46, 234–243, 2010.
   PubMed Web of Science ®Google Scholar
• Sharif R, Thomas P, Zalewski P, Graham RD, and Fenech M: The effect of zinc sulphate and zinc carnosine on genome stability and cytotoxicity in the WIL2-NS human lymphoblastoid cell line. Mutat Res 720, 22–33, 2011.
   PubMed Web of Science ®Google Scholar
• Sharif R, Thomas P, Zalewski P, and Fenech M: Zinc deficiency or excess within the physiological range increases genome instability and cytotoxicity, respectively, in human oral keratinocyte cells. Genes Nutr 7, 139–154, 2012.
   PubMed Web of Science ®Google Scholar
• Ooi TC, Mohammad NH, and Sharif R: Zinc carnosine protects against hydrogen peroxide-induced DNA damage in WIL2-NS lymphoblastoid cell line independent of poly (ADP-ribose) polymerase expression. Biol Trace Elem Res 162, 8–17, 2014.
   PubMed Web of Science ®Google Scholar
• Sharif R, Thomas P, Zalewski P, and Fenech M: Zinc supplementation influences genomic stability biomarkers, antioxidant activity, and zinc transporter genes in an elderly Australian population with low zinc status. Mol Nutr Food Res 59, 1200–1212, 2015.
   PubMed Web of Science ®Google Scholar
• Klaunig JE and Kamendulis LM: The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44, 239–267, 2004.
   PubMed Web of Science ®Google Scholar
• Multhoff G, Molls M, and Radons J: Chronic inflammation in cancer development. Front Immunol 2, 98, 2011.
   PubMed Web of Science ®Google Scholar
• Shen Z: Genomic instability and cancer: an introduction. J Mol Cell Biol 3, 1–3, 2011.
   PubMed Web of Science ®Google Scholar
• Powell SR: The antioxidant properties of zinc. J Nutr 130, 1447s–1454s, 2000.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Naito Y, Tanigawa T, Yoneta T, Oyamada H, et al.: Effect of zinc-carnosine chelate compound (Z-103) on burn-induced gastric mucosal injury in rats. J Clin Biochem Nutr 7, 107–113, 1989.
   Web of Science ®Google Scholar
• Ito M, Shii D, Segami T, Kojima R, and Suzuki Y: Preventive actions of N-(3-aminopropionyl)-l-histidinato zinc (Z-103) through increases in the activities of oxygen-derived free radical scavenging enzymes in the gastric mucosa on ethanol-induced gastric mucosal damage in rats. Jpn J Pharmacol 59, 267–274, 1992.
   PubMedGoogle Scholar
• Choi HS, Lim JY, Chun HJ, Lee M, Kim ES, et al.: The effect of polaprezinc on gastric mucosal protection in rats with ethanol-induced gastric mucosal damage: comparison study with rebamipide. Life Sci 93, 69–77, 2013.
   PubMed Web of Science ®Google Scholar
• Ueda K, Ueyama T, Oka M, Ito T, Tsuruo Y, et al.: Polaprezinc (zinc l-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1—a new mechanism of gastric mucosal protection. J Pharmacol Sci 110, 285–294, 2009.
   PubMed Web of Science ®Google Scholar
• Gozzelino R, Jeney V, and Soares MP: Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 50, 323–354, 2010.
   PubMed Web of Science ®Google Scholar
• Ohkawara T, Nishihira J, Nagashima R, Takeda H, and Asaka M: Polaprezinc protects human colon cells from oxidative injury induced by hydrogen peroxide: relevant to cytoprotective heat shock proteins. World J Gastroenterol 12, 6178–6181, 2006.
   PubMed Web of Science ®Google Scholar
• Feder ME and Hofmann GE: Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Annu Rev Physiol 61, 243–282, 1999.
   PubMed Web of Science ®Google Scholar
• Li Y and Maret W: Human metallothionein metallomics. J Anal At Spectrom 23, 1055, 2008.
   Web of Science ®Google Scholar
• Ruttkay-Nedecky B, Nejdl L, Gumulec J, Zitka O, Masarik M, et al.: The role of metallothionein in oxidative stress. Int J Mol Sci 14, 6044–6066, 2013.
   PubMed Web of Science ®Google Scholar
• Matsukura T and Tanaka H: Applicability of zinc complex of l-carnosine for medical use. Biochemistry (Mosc) 65, 817–823, 2000.
   PubMed Web of Science ®Google Scholar
• Naito Y, Yoshikawa T, Yagi N, Matsuyama K, Yoshida N, et al.: Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-alpha expression in rats with aspirin-induced gastric mucosal injury. Dig Dis Sci 46, 845–851, 2001.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Mori M, Seto K, Miyazawa M, Kai A, et al.: Polaprezinc attenuates the Helicobacter pylori-induced gastric mucosal leucocyte activation in Mongolian gerbils—a study using intravital videomicroscopy. Aliment Pharmacol Ther 15, 715–725, 2001.
   PubMed Web of Science ®Google Scholar
• Ishihara R, Iishi H, Sakai N, Yano H, Uedo N, et al.: Polaprezinc attenuates Helicobacter pylori-associated gastritis in Mongolian gerbils. Helicobacter 7, 384–389, 2002.
   PubMed Web of Science ®Google Scholar
• Handa O, Yoshida N, Tanaka Y, Ueda M, Ishikawa T, et al.: Inhibitory effects of polaprezine on the inflammatory response to Helicobacter pylori. Can J Gastroenterol 16, 785–789, 2002.
   PubMed Web of Science ®Google Scholar
• Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1, a001651, 2009.
   PubMed Web of Science ®Google Scholar
• Odashima M, Otaka M, Jin M, Wada I, Horikawa Y, et al.: Zinc l-carnosine protects colonic mucosal injury through induction of heat shock protein 72 and suppression of NF-kappaB activation. Life Sci 79, 2245–2250, 2006.
   PubMed Web of Science ®Google Scholar
• Ooi TC, Chan KM, and Sharif R: Zinc carnosine inhibits lipopolysaccharide-induced inflammatory mediators by suppressing NF-kappaB activation in raw 264.7 macrophages, independent of the MAPKs signaling pathway. Biol Trace Elem Res 172, 458–464, 2016.
   PubMed Web of Science ®Google Scholar
• Yoo CG, Lee S, Lee CT, Kim YW, Han SK, et al.: Anti-inflammatory effect of heat shock protein induction is related to stabilization of I B through preventing I B kinase activation in respiratory epithelial cells. J Immunol 164, 5416–5423, 2000.
   PubMed Web of Science ®Google Scholar
• King TA, Ghazaleh RA, Juhn SK, Adams GL, and Ondrey FG: Induction of heat shock protein 70 inhibits NF-kappa-B in squamous cell carcinoma. Otolaryngol Head Neck Surg 133, 70–79, 2005.
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Xiao W, Wang H, Calderwood SK, et al.: The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J Immunol 179, 1236–1244, 2007.
   PubMed Web of Science ®Google Scholar
• Kryston TB, Georgiev AB, Pissis P, and Georgakilas AG: Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 711, 193–201, 2011.
   PubMed Web of Science ®Google Scholar
• Hoesel B and Schmid JA: The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 12, 86, 2013.
   PubMed Web of Science ®Google Scholar
• Sharma S, Kelly TK, and Jones PA: Epigenetics in cancer. Carcinogenesis 31, 27–36, 2010.
   PubMed Web of Science ®Google Scholar